CD8A and neoplasm: Although the transfer of RepTILs and subsequent trametinib treatment induced modest control of smaller CRLM-derived tumors, we utilized our PDX model to address the fate of transferred RepTILs, particularly whether trametinib increased their presence in the autologous tumor as activated CD8+ TRM cells (Figure 4A–C).